PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,690,918 | PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates In force · High confidence | ADC Therapeutics S.A. | In force | High confidence | ||
| US 10,722,594 | PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates In force · High confidence | ADC Therapeutics S.A. | In force | High confidence | ||
| US 9,919,056 | PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates Lapsed Mar 20, 2026 on the fee record Ended Mar 20, 2026 · High confidence | ADC Therapeutics S.A. | Lapsed Mar 20, 2026 on the fee record | Ended Mar 20, 2026 | High confidence |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by ADC GmbH.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.